Compare Canopy Growth Corp (CGC) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Cigna Corp — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Cigna Corp trades at $277.72 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 174.7× Canopy Growth Corp's market cap, and Cigna Corp pays a 2.24% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | CI | |
|---|---|---|
Market Cap | $421.10M | $73.56B |
Sector | Health | Health |
52-Week High | $1.92 | $311.00 |
52-Week Low | $0.86 | $244.41 |
Enterprise Value | $378.55M | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Cigna (CI) trades at $275.4, down 1.08% today, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, including a low P/E of 11.51 and consistent earnings beats, with Q2 2026 EPS of $7.78 exceeding expectations. Recent news highlights raised 2026 EPS guidance to at least $30.45, driven by growth in health services and insurance segments.
The outlook is positive, supported by analyst consensus with a $338.90 price target and 73.68% buy ratings. Key risks include competitive pressures and regulatory changes in healthcare. The valuation gap presents an opportunity, but investors should monitor medical cost trends and execution of growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
